Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Evolocumab

Brand: Repatha┬«
NICE TA: 
Indication: Prevention of cardiac events in patients with CHD and a history of ACS, in combination with a statin
Disease category: Cardiovascular system
Commissioning responsibility: CCG
PbR excluded: No

Background

The evidence for evolocumab in the setting of patients with CHD and a history of ACS, in combination with a statin was reviewed however this did not provide adequate cost effectiveness data to allow use in patients in addition to those covered by NICE TA394

Recommendation

LMMG recommendation: Black
Click here to find the definitions for the colour classifications

Reason for decision:  Not recommended for prescribing on the NHS in Lancashire

Supporting documents:

LMMG New Medicine Recommendation - Evolocumab (516.6 KiB)

Evolocumab for NICE TA394

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Black

Black

Black

Black

Black

Black